The results of the study conducted by the UK Health Security Agency (UKHSA) in collaboration with HIPRA demonstrate the ability of PHH-1V (recombinant heterodimeric beta-alpha fusion protein vaccine) to induce immune responses from early variants (Victoria 1/2020 WT), responsible for severe infections, to more recent variants (Omicron BA.5, XBB1.16, EG5.1, and BA2.86), associated with milder infections. These findings align with those previously observed in clinical studies conducted with the PHH-1V vaccine.